Gupta R K
Cytology Unit, Wellington Hospital and School of Medicine, Wellington, and Valley Diagnostic Laboratories, Ltd., Lower Hutt, New Zealand.
Diagn Cytopathol. 1999 Sep;21(3):167-9. doi: 10.1002/(sici)1097-0339(199909)21:3<167::aid-dc4>3.0.co;2-w.
Prostatic-specific antigen (PSA) is regarded as a specific marker secreted by normal and neoplastic acinar epithelial cells of the prostate gland; its detection by immunocytochemistry has been accepted as an indication of metastatic prostate cancer. This is ascribed to the commonly held belief that PSA is not found in extraprostatic tissues. However, this concept has recently been challenged, based on the observations that certain nonprostatic tissues and their neoplasms can also secrete PSA. Such a questionable belief could result in a diagnostic pitfall when using immunostaining for PSA on fine-needle aspiration (FNAC) cytology samples to differentiate metastatic prostate cancer from a primary carcinoma of an extraprostatic organ. In this communication, two cases of primary carcinomas of the male breast are reported in which PSA immunopositivity on FNAC led to the suggestion of a diagnosis of metastatic carcinoma of the prostate. Diagn. Cytopathol. 1999;21:167-169.
前列腺特异性抗原（PSA）被视为前列腺正常和肿瘤性腺泡上皮细胞分泌的一种特异性标志物；通过免疫细胞化学检测PSA已被视为转移性前列腺癌的一个指标。这归因于人们普遍认为在前列腺外组织中找不到PSA。然而，基于某些非前列腺组织及其肿瘤也能分泌PSA这一观察结果，这一概念最近受到了挑战。当在细针穿刺（FNAC）细胞学样本上使用PSA免疫染色来区分转移性前列腺癌和前列腺外器官的原发性癌时，这种有问题的观念可能会导致诊断陷阱。在本交流中，报告了2例男性乳腺癌原发性癌病例，其中FNAC上的PSA免疫阳性提示诊断为前列腺转移性癌。《诊断细胞病理学》1999年；21:167 - 169。
